Home
InnoCare Pharma Limited

InnoCare Pharma Limited Market Share Analysis for June 2026

Health > Biotechnology and Pharmaceuticals

Domaininnocarepharma.com

Year Founded2013

Employees1001 - 5000

Annual Revenue$5M - $10M

InnoCare Pharma Limited

InnoCare Pharma Limited (including company regionals)

innocarepharma.com

See more website traffic and engagement information

InnoCare Pharma Limited Revenue up to June 2026 is 5M - 10M

revenue generated by InnoCare Pharma Limited top domains

InnoCare Pharma Limited top domains revenue over 3 years

Revenue for InnoCare Pharma Limited top domains

innocarepharma.com5M - 10M

See more with Sales Intelligence

Total visits to InnoCare Pharma Limited's top domains

Understand InnoCare Pharma Limited market share and potential market reach.

Total visits last 3 months

Subsidiaries Breakdown

innocarepharma.com5.6K

See more with Sales Intelligence

Avg. visit duration in InnoCare Pharma Limited's top domains

Analyze InnoCare Pharma Limited engagement metrics.

Average visit duration last 3 months

Subsidiaries Breakdown

innocarepharma.com00:00:55

See more with Sales Intelligence

Avg. pageviews on InnoCare Pharma Limited's top domains

See how InnoCare Pharma Limited keep users engaged, nurture their interest, and encourage them to take the next step.

Average page views last 3 months

Subsidiaries Breakdown

innocarepharma.com1.70

See more with Sales Intelligence

InnoCare Pharma Limited top competitors by domain

Top similar sites in June 2026, ranked by their affinity

springermedicine.comCompany NameSpringer MedizinEmployees201 - 500HQGermany, BerlinAnnual revenue--Total visits371.6KHealth > Medicine

Top technologies used by InnoCare Pharma Limited

These are the website technologies, by industry, used by InnoCare Pharma Limited top domains

Conversion & Analytics (4)

Google Analytics

Social (3)

Instagram

Payment & Currencies (2)

Cart Functionality

Advertising (1)

Baidu Ads

More Technologies

6

See all

News & Signals from InnoCare Pharma Limited

With Similarweb Sales signals alerts, you’ll receive daily updates of recognized buying signals whenever new opportunities or threats arise in your target audience.

NewsKeymed partners with Innocarepharma.PRO-203 was originally developed as CM355 by HKEX-listed KeyMed Biosciences (HKEX: 02162), subsequently co-developed with InnoCare Pharma (HKEX: 09969; SSE: 688428) as ICP-B02 under a 50/50 joint venture, and in-licensed by Prolium Bioscience in January 2025 for global non-oncology rights and ex-Asia oncology rights, with aggregate milestone payments of up to USD 520 million disclosed.

NewsInnocarepharma attended event European Hematology Association (EHA) 2026 Congress on Jun 15th '26.Beijing, June 15, 2026 - InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that over 40 clinical studies of the Company's novel BTK inhibitor orelabrutinib were presented at the European Hematology Association (EHA) 2026 Congress.

NewsInnocarepharma attended event 2026 American Society of Clinical Oncology (ASCO) Annual Meeting on Apr 21st '26.Beijing, Jun 3, 2026 - InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that the updated data of the Company's novel BCL2 inhibitor mesutoclax in myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) has been released at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting as an oral presentation entitled as "Safety, tolerability, and efficacy of mesutoclax (ICP-248) in combination with azacitidine in patients with myeloid malignancies", demonstrating outstanding efficacy and safety.